Skip to Content
Address: 5219 MERF
Phone: (319) 335-8272
Mentor: Raymond Hohl, MD, PhD
Undergraduate Institution: Creighton University, BS
Year Entered Into Program: 2011
Prostate carcinoma is the most common cancer of males in the United States and the second most deadly cancer. Of the prostate cancer deaths, more than 80% will have skeletal metastasis, making novel cancer treatments and adjunct therapies targeting metastasis vital in decreasing death rates. One proposed scheme of cancer metastasis utilizes previous work establishing the general importance and sufficiency of the Rho family in altering proteins involved in cell survival, cell cycle and the proteolysis step of invasion. While a majority of the work has focused on Rho family mRNA and selective cancers, protein activity at various stages of cancer metastasis and inhibition of specific Rho proteins have not been explored. Utilizing nitrogenous bisphosphonates as inhibitors upstream of the Rho GTPase family both in vivo and in vitro, we hope to elucidate the mechanism by which the modified Rho subfamily of proteins are able to promote tumorigenesis, in addition to testing various bisphosphonates as novel prostate cancer adjunct therapies.
Fletcher, J.T. and Reilly, J.E.: Fast dye salts provide fast access to azidoarene synthons in multi-step one-pot tandem click transformations. Tetrahedron Lett. 52(42):5512-5515, 2011. PMCID: PMC3285242
Copyright © 2011 The University of Iowa. All Rights Reserved.